NCT06715592View on ClinicalTrials.gov

ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

February 1, 2027

Conditions
Paget Disease of the VulvaVulva Cancer
Interventions
DRUG

Bleomicina

Colposcopically guided ECT following intralesional administration / intravenous Bleomycin or intralesional Cisplatin according to ESOPE recommendations. Reassessment after 30 days by colposcopy and conization with acquisition of histological examination.

Trial Locations (1)

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER